Humacyte Appointed Two New Board Members
The Durham-based firm has expanded its leadership team to bolster its global commercial operations.
Updated on Sept. 28, 2026 in People
Live Poll
Do you trust biotechnology companies to prioritize patient health alongside their commercial growth?
Humacyte has appointed Scott Coward and Paul Kuznik to its Board of Directors. The expansion aims to strengthen the company as it prepares for the commercial launch of its tissue engineered vessel.
Why it matters
The appointments provide Humacyte with additional executive expertise to support its global growth. This strategic move follows the company's recent federal approval for its flagship medical technology.
Paul Kuznik brings 30 years of medical technology experience to the role, while the company prepares to market its 6mm acellular tissue engineered vessel. These leadership additions follow the FDA's December 2024 approval of the device.
The players
Humacyte
This Durham-based biotechnology company specializes in developing human acellular tissue engineered products for various medical indications.
Scott Coward
He is a new member of the board and previously served as an executive at Exact Sciences Corporation.
Paul Kuznik
He joins the board after a three-decade career in the medical technology sector, including time as the President of Terumo Aortic North America.
The details
Scott Coward, formerly an executive at Exact Sciences Corporation, will serve on the Audit Committee. Paul Kuznik, who previously led Terumo Aortic North America, has joined the Commercial Committee to help guide global operations.
Timeline
December 2024: The FDA approved the acellular tissue engineered vessel.
September 28, 2026: Humacyte announced the appointment of two board members.
Market Landscape
This strategic growth reflects a broader industry pattern where biotech firms pivot from clinical trial phases to commercial scaling after regulatory success. By securing experienced leadership, the company aims to solidify its competitive position against other medical device manufacturers.
While these board appointments do not immediately affect daily retail prices, they signal the company's intent to bring its dialysis access technology to market. Patients and providers can expect updates on the commercial availability of the product in the coming months.
The takeaway
Adding veteran executives to a board is a critical step for companies transitioning from clinical development to wide-scale distribution. Investors and observers often monitor these moves as indicators of a firm's readiness to execute complex global market strategies.
Further reading
Learn more about the latest leadership developments in the People section of our site.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust biotechnology companies to prioritize patient health alongside their commercial growth?
